Recherchemedicale.com
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérocycliques avec 4 noyaux ou plus
Ergolines
Ergolines : Questions médicales fréquentes
Diagnostic
5
Tests diagnostiques
Ergolines
Interactions médicamenteuses
Ergolines
Critères cliniques
Ergolines
Symptômes
5
Effets secondaires
Ergolines
Système nerveux
Ergolines
Problèmes cardiovasculaires
Ergolines
Symptômes psychologiques
Ergolines
Prévention
5
Sensibilisation
Ergolines
Interactions médicamenteuses
Ergolines
Traitements
5
Antipsychotiques
Ergolines
Traitements symptomatiques
Ergolines
Complications
5
Maladies chroniques
Ergolines
Risques à long terme
Ergolines
Facteurs de risque
5
Facteurs de risque
Ergolines
Personnes âgées
Ergolines
Médicaments concomitants
Ergolines
Troubles mentaux
Ergolines
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Ergolines : Questions médicales les plus fréquentes",
"headline": "Ergolines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Ergolines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-05",
"dateModified": "2024-12-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Ergolines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Composés hétérocycliques avec 4 noyaux ou plus",
"url": "https://recherchemedicale.com/mesh/D006576",
"about": {
"@type": "MedicalCondition",
"name": "Composés hétérocycliques avec 4 noyaux ou plus",
"code": {
"@type": "MedicalCode",
"code": "D006576",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cabergoline",
"alternateName": "Cabergoline",
"url": "https://recherchemedicale.com/mesh/D000077465",
"about": {
"@type": "MedicalCondition",
"name": "Cabergoline",
"code": {
"@type": "MedicalCode",
"code": "D000077465",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.197"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Ergométrine",
"alternateName": "Ergonovine",
"url": "https://recherchemedicale.com/mesh/D004874",
"about": {
"@type": "MedicalCondition",
"name": "Ergométrine",
"code": {
"@type": "MedicalCode",
"code": "D004874",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.262"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Méthylergométrine",
"alternateName": "Methylergonovine",
"url": "https://recherchemedicale.com/mesh/D008755",
"about": {
"@type": "MedicalCondition",
"name": "Méthylergométrine",
"code": {
"@type": "MedicalCode",
"code": "D008755",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.262.538"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Lisuride",
"alternateName": "Lisuride",
"url": "https://recherchemedicale.com/mesh/D008090",
"about": {
"@type": "MedicalCondition",
"name": "Lisuride",
"code": {
"@type": "MedicalCode",
"code": "D008090",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.560"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Acide lysergique",
"alternateName": "Lysergic Acid",
"url": "https://recherchemedicale.com/mesh/D008237",
"about": {
"@type": "MedicalCondition",
"name": "Acide lysergique",
"code": {
"@type": "MedicalCode",
"code": "D008237",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.572"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Lysergide",
"alternateName": "Lysergic Acid Diethylamide",
"url": "https://recherchemedicale.com/mesh/D008238",
"about": {
"@type": "MedicalCondition",
"name": "Lysergide",
"code": {
"@type": "MedicalCode",
"code": "D008238",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.572.522"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Métergoline",
"alternateName": "Metergoline",
"url": "https://recherchemedicale.com/mesh/D008711",
"about": {
"@type": "MedicalCondition",
"name": "Métergoline",
"code": {
"@type": "MedicalCode",
"code": "D008711",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.630"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Méthysergide",
"alternateName": "Methysergide",
"url": "https://recherchemedicale.com/mesh/D008784",
"about": {
"@type": "MedicalCondition",
"name": "Méthysergide",
"code": {
"@type": "MedicalCode",
"code": "D008784",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.689"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nicergoline",
"alternateName": "Nicergoline",
"url": "https://recherchemedicale.com/mesh/D009530",
"about": {
"@type": "MedicalCondition",
"name": "Nicergoline",
"code": {
"@type": "MedicalCode",
"code": "D009530",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.730"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Pergolide",
"alternateName": "Pergolide",
"url": "https://recherchemedicale.com/mesh/D010479",
"about": {
"@type": "MedicalCondition",
"name": "Pergolide",
"code": {
"@type": "MedicalCode",
"code": "D010479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.400.439.800"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Ergolines",
"alternateName": "Ergolines",
"code": {
"@type": "MedicalCode",
"code": "D004873",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yongpeng Yao",
"url": "https://recherchemedicale.com/author/Yongpeng%20Yao",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China."
}
},
{
"@type": "Person",
"name": "Chunyan An",
"url": "https://recherchemedicale.com/author/Chunyan%20An",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China."
}
},
{
"@type": "Person",
"name": "Declan Evans",
"url": "https://recherchemedicale.com/author/Declan%20Evans",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry and Biochemistry , University of California , Los Angeles California 90095 , United States."
}
},
{
"@type": "Person",
"name": "Weiwei Liu",
"url": "https://recherchemedicale.com/author/Weiwei%20Liu",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China."
}
},
{
"@type": "Person",
"name": "Wei Wang",
"url": "https://recherchemedicale.com/author/Wei%20Wang",
"affiliation": {
"@type": "Organization",
"name": "State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Synthetic Strategies toward Lysergic Acid Diethylamide: Ergoline Synthesis via α-Arylation, Borrowing Hydrogen Alkylation, and C-H Insertion.",
"datePublished": "2023-09-11",
"url": "https://recherchemedicale.com/article/37697477",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.joc.3c01363"
}
},
{
"@type": "ScholarlyArticle",
"name": "Quantification of Ergot Alkaloids via Lysergic Acid Hydrazide-Development and Comparison of a Sum Parameter Screening Method.",
"datePublished": "2023-04-25",
"url": "https://recherchemedicale.com/article/37175111",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules28093701"
}
},
{
"@type": "ScholarlyArticle",
"name": "How to manage intolerance to dopamine agonist in patients with prolactinoma.",
"datePublished": "2023-04-07",
"url": "https://recherchemedicale.com/article/37027090",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11102-023-01313-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients.",
"datePublished": "2022-10-07",
"url": "https://recherchemedicale.com/article/36206759",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-1930-6585"
}
},
{
"@type": "ScholarlyArticle",
"name": "Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature.",
"datePublished": "2023-03-17",
"url": "https://recherchemedicale.com/article/36927797",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13256-023-03820-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://recherchemedicale.com/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://recherchemedicale.com/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérocycliques avec 4 noyaux ou plus",
"item": "https://recherchemedicale.com/mesh/D006576"
},
{
"@type": "ListItem",
"position": 5,
"name": "Ergolines",
"item": "https://recherchemedicale.com/mesh/D004873"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Ergolines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Ergolines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-01-23",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Ergolines",
"description": "Comment diagnostiquer une intoxication aux ergolines ?\nQuels tests sont utilisés pour évaluer l'effet des ergolines ?\nQuels symptômes indiquent un surdosage d'ergolines ?\nComment différencier les effets des ergolines des autres médicaments ?\nQuels critères cliniques sont utilisés pour le diagnostic ?",
"url": "https://recherchemedicale.com/mesh/D004873#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Ergolines",
"description": "Quels sont les symptômes courants des ergolines ?\nLes ergolines provoquent-elles des effets secondaires ?\nComment les ergolines affectent-elles le système nerveux ?\nLes ergolines causent-elles des problèmes cardiovasculaires ?\nQuels symptômes psychologiques sont associés aux ergolines ?",
"url": "https://recherchemedicale.com/mesh/D004873#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Ergolines",
"description": "Comment prévenir l'intoxication aux ergolines ?\nQuelles précautions prendre lors de l'utilisation d'ergolines ?\nLes femmes enceintes doivent-elles éviter les ergolines ?\nComment sensibiliser sur les risques des ergolines ?\nLes interactions médicamenteuses peuvent-elles être évitées ?",
"url": "https://recherchemedicale.com/mesh/D004873#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Ergolines",
"description": "Comment traiter une intoxication aux ergolines ?\nQuels médicaments sont utilisés pour contrer les effets des ergolines ?\nY a-t-il des traitements spécifiques pour les effets secondaires ?\nComment gérer les effets à long terme des ergolines ?\nLes ergolines nécessitent-elles un sevrage ?",
"url": "https://recherchemedicale.com/mesh/D004873#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Ergolines",
"description": "Quelles sont les complications possibles des ergolines ?\nLes ergolines peuvent-elles causer des maladies chroniques ?\nComment les ergolines affectent-elles la santé mentale ?\nLes complications sont-elles réversibles ?\nQuels sont les risques à long terme des ergolines ?",
"url": "https://recherchemedicale.com/mesh/D004873#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Ergolines",
"description": "Quels sont les facteurs de risque d'intoxication aux ergolines ?\nLes personnes âgées sont-elles plus à risque ?\nL'usage concomitant d'autres médicaments augmente-t-il le risque ?\nLes antécédents de troubles mentaux sont-ils un facteur de risque ?\nLe mode de vie influence-t-il le risque d'intoxication ?",
"url": "https://recherchemedicale.com/mesh/D004873#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux ergolines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique médical et des tests sanguins pour détecter les ergolines."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'effet des ergolines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests neurologiques et psychologiques peuvent être réalisés pour évaluer l'effet des ergolines."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un surdosage d'ergolines ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des hallucinations, des nausées et des troubles cardiaques peuvent indiquer un surdosage."
}
},
{
"@type": "Question",
"name": "Comment différencier les effets des ergolines des autres médicaments ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une analyse des antécédents médicaux et des interactions médicamenteuses aide à cette différenciation."
}
},
{
"@type": "Question",
"name": "Quels critères cliniques sont utilisés pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères incluent l'évaluation des symptômes neurologiques et psychiatriques associés aux ergolines."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des ergolines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des vertiges, des nausées, des hallucinations et des troubles de la mémoire."
}
},
{
"@type": "Question",
"name": "Les ergolines provoquent-elles des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des troubles gastro-intestinaux et des réactions allergiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les ergolines affectent-elles le système nerveux ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des modifications de l'humeur, des troubles cognitifs et des hallucinations."
}
},
{
"@type": "Question",
"name": "Les ergolines causent-elles des problèmes cardiovasculaires ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des vasoconstrictions et des troubles du rythme cardiaque."
}
},
{
"@type": "Question",
"name": "Quels symptômes psychologiques sont associés aux ergolines ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'anxiété, la dépression et des hallucinations peuvent être observés."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'intoxication aux ergolines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter l'usage non médical et suivre les prescriptions médicales peut prévenir l'intoxication."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre lors de l'utilisation d'ergolines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est important de suivre les doses prescrites et de consulter un médecin en cas d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles éviter les ergolines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes enceintes doivent éviter les ergolines en raison des risques pour le fœtus."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser sur les risques des ergolines ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et des consultations médicales peuvent sensibiliser aux risques."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses peuvent-elles être évitées ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en informant le médecin de tous les médicaments pris, les interactions peuvent être évitées."
}
},
{
"@type": "Question",
"name": "Comment traiter une intoxication aux ergolines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'arrêt du médicament, des soins de soutien et parfois des antidotes spécifiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour contrer les effets des ergolines ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme les antipsychotiques peuvent être utilisés pour traiter les effets indésirables."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements spécifiques pour les effets secondaires ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements symptomatiques comme des antiémétiques peuvent être administrés."
}
},
{
"@type": "Question",
"name": "Comment gérer les effets à long terme des ergolines ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance régulière et un suivi psychologique peuvent aider à gérer les effets à long terme."
}
},
{
"@type": "Question",
"name": "Les ergolines nécessitent-elles un sevrage ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un sevrage progressif est recommandé pour éviter des symptômes de sevrage sévères."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles des ergolines ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles cardiovasculaires, neurologiques et psychiatriques graves."
}
},
{
"@type": "Question",
"name": "Les ergolines peuvent-elles causer des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une utilisation prolongée peut entraîner des maladies chroniques comme la fibrose pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment les ergolines affectent-elles la santé mentale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent exacerber des troubles mentaux préexistants et provoquer des psychoses."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Quels sont les risques à long terme des ergolines ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des troubles neurologiques persistants et des problèmes cardiovasculaires chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'intoxication aux ergolines ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'usage récréatif, les antécédents médicaux et les interactions médicamenteuses."
}
},
{
"@type": "Question",
"name": "Les personnes âgées sont-elles plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent être plus sensibles aux effets des ergolines en raison de comorbidités."
}
},
{
"@type": "Question",
"name": "L'usage concomitant d'autres médicaments augmente-t-il le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'usage concomitant d'autres médicaments peut augmenter le risque d'effets indésirables."
}
},
{
"@type": "Question",
"name": "Les antécédents de troubles mentaux sont-ils un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de troubles mentaux augmentent le risque de complications liées aux ergolines."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque d'intoxication ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie à risque, comme la consommation de drogues, augmente le risque d'intoxication."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 31/12/2024
Contenu vérifié selon les dernières recommandations médicales
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry , University of California , Los Angeles California 90095 , United States.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China.
University of Chinese Academy of Sciences , Beijing 100049 , P. R. China.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China.
University of Chinese Academy of Sciences , Beijing 100049 , P. R. China.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
School of Food Science and Technology , Jiangnan University , Wuxi , Jiangsu 214122 , P. R. China.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry , University of California , Los Angeles California 90095 , United States.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
State Key Laboratory of Microbial Resources , Institute of Microbiology, Chinese Academy of Sciences , Beijing 100101 , P. R. China.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Davis, Davis, California 95616, United States.
Institute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, California 95616, United States.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Davis, Davis, California 95616, United States.
Institute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, California 95616, United States.
Publications dans "Ergolines" :
1 publication dans cette catégorie
Affiliations :
Department of Chemistry, University of California, Davis, Davis, California 95616, United States.
Institute for Psychedelics and Neurotherapeutics, University of California, Davis, Davis, California 95616, United States.
Department of Biochemistry & Molecular Medicine, School of Medicine, University of California, Davis, Sacramento, California 95817, United States.
Center for Neuroscience, University of California, Davis, Davis, California 95618, United States.
Publications dans "Ergolines" :
Lysergic acid diethylamide (LSD), a semisynthetic ergoline alkaloid analogue and hallucinogen, is a potent psychoplastogen with promising therapeutic potential. While a variety of synthetic strategies...
Ergot alkaloids are a group of mycotoxins occurring in products derived from various grasses (e.g., rye) and have been regulated in the EU recently. The new maximum levels refer to the sum of the six ...
Dopamine agonists (DA) are the gold-standard for prolactinoma and hyperprolactinemia treatment. Intolerance to DA leading to drug drop out occurs in 3 to 12% of cases. We provide here a review of publ...
We review the literature on the definition, the pathogenesis, frequency and management of DA intolerance. In addition, the review provides strategies to enhance tolerability and avoid precocious clini...
Cabergoline is often cited as the most tolerable DA and its side effects tend to ameliorate within days to weeks. Restarting the same drug at a lower dose or switching to another DA can be used in cas...
Due to limited data, no guidelines have been developed for the management of intolerance in DA treatment. The most frequent management is to perform transsphenoidal surgery. Nevertheless, this manuscr...
The aim of this study was to evaluate the efficacy of cabergoline in normalizing plasma IGF-I levels in acromegaly patients with elevated IGF-I levels after surgery and/or SRL therapy. Acromegaly pati...
Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only ...
A 63-year-old Chinese man presented with blurred vision and was subsequently diagnosed with a macroprolactinoma. He had initial response to cabergoline but developed secondary resistance to it after 5...
Surgery can facilitate disease control in patients with prolactinomas that develop secondary resistance to dopamine agonists. Malignant prolactinoma is an important differential diagnosis in this grou...
Hypogonadism is the most common form of hypopituitarism in men with macroprolactinoma. However, evidence on factors related to hypogonadism recovery is limited....
We estimated the proportion of hypogonadism in men with macroprolactinoma exclusively treated with dopamine agonists, and we assessed the factors predicting hypogonadism recovery....
This was a multicenter retrospective study of men with macroprolactinoma identified using ICD 9 and 10 codes and treated between 2009 and 2019 in five centers in the United Arab Emirates and Saudi Ara...
A total of 79 patients (median age 32 years) were included in the study. The most common symptoms at presentation were headache (73.7%), erectile dysfunction (55.4%), and low libido (54.3%). The media...
About two-thirds of men with macroprolactinoma recover from hypogonadism, mostly with 24 months of therapy. Smaller adenoma size, lower prolactin level, earlier prolactin normalization, and higher tes...
The enantioselective synthesis of (+)-isolysergol was completed in 18 steps, and an overall yield of 11% was obtained from (2...
Giant prolactinomas (GP) are rare tumors accounting for 4.3% of prolactinomas, with paucity of literature from India. We aim to describe clinical, biochemical, radiological, and treatment outcomes in ...
A single-center retrospective analysis of GPs (n=84), age-based (adults: 66 versus pediatric: 18) and gender-based (males: 64 versus females: 20) comparison was done....
The mean age at presentation was 34.1±13years, and 64 (76.2%) were males. Males were younger at presentation (32.1±12.2 versus 40.1±13.8years, P: 0.01). The majority presented with mass-effect-related...
GP has male predominance, DA as first-line therapy normalized prolactin in four-fifths of patients with better preservation of HPT and HPA axes in patients with DA monotherapy....
Key transformations in a four-step synthesis of the...
A 22-year-old man complaining erectile dysfunction underwent transsphenoidal surgery for a 2.7 cm sellar mass with total resection and was confirmed at pathology to have a lactotroph pituitary neuroen...
In this study, the patient was given hydroxychloroquine (HCQ) (200 mg/d) and CAB (3 mg/w) in combination for four months. His PRL level was tested by blood test every month....
Taking the combination therapy of HCQ and CAB, the patient's uncontrolled PRL level was normalized within one month and was maintained at the normal level thereafter. Pituitary magnetic resonance imag...
This is the first report on the combination of HCQ with CAB for the effective treatment of DA-resistant lactotroph pituitary neuroendocrine tumor in a patient, which might provide a novel treatment st...